STOCK TITAN

Delcath Systems to Participate at Upcoming Virtual Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Delcath Systems (DCTH) announced its participation in two upcoming virtual investor conferences. The HC Wainwright Global Life Sciences Conference will occur on March 9, 2021, with on-demand viewing starting at 7:00 AM (ET). A webcast link is available for attendees. Additionally, Delcath will attend the 33rd Annual Roth Conference, scheduled for March 15-17, 2021, allowing for 1x1 meetings only. Delcath focuses on oncology treatments for liver cancers, with its investigational product, HEPZATO KIT, targeting high-dose chemotherapy treatment.

Positive
  • None.
Negative
  • None.

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences: 

For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com


FAQ

What conferences is Delcath Systems participating in March 2021?

Delcath Systems will participate in the HC Wainwright Global Life Sciences Conference on March 9, 2021, and the Roth Conference from March 15-17, 2021.

What time does the HC Wainwright Conference start for Delcath Systems?

The HC Wainwright Global Life Sciences Conference starts at 7:00 AM (ET) on March 9, 2021.

What is the focus of Delcath Systems?

Delcath Systems specializes in the treatment of rare primary and metastatic liver cancers through interventional oncology.

What product does Delcath Systems offer for liver cancer treatment?

Delcath Systems' investigational product is HEPZATO KIT, designed for high-dose chemotherapy delivery to the liver.

Is HEPZATO KIT approved by the FDA?

HEPZATO KIT has not been approved by the U.S. Food & Drug Administration for sale in the U.S.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

349.79M
29.73M
2.71%
38.13%
4.46%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
QUEENSBURY